Table 1.
Patient and disease characteristics at baseline
| Characteristics | Number of Patients (%) |
|---|---|
| Sex | |
| Male | 31 (82%) |
| Female | 7 (18%) |
| Median age (range) | 60 years (42–74) |
| Nicotine abuse | |
| Yes | 26 (81.3%) |
| No | 6 (18.7%) |
| Not evaluable | 6 |
| Alcohol abuse | |
| Yes | 16 (50%) |
| No | 16 (50%) |
| Not evaluable | 6 |
| Primary tumor site | |
| Hypopharynx | 1 (2.6%) |
| Oral cavity | 17 (44.7%) |
| Oropharynx | 11 (28.9%) |
| Larynx | 5 (17.9%) |
| Double locations | 4 (10.5%) |
| p16 status (oropharyngeal carcinoma) | |
| Positive | 5 (45.5%) |
| Negative | 6 (54.5%) |
| Cycles (range) | 3 (1–7) |
| Median duration of treatment | 2.6 months |
| Previous treatment | |
| Primary treatment | |
| No primary treatment | 4 (10.5%) |
| Surgery alone | 8 (21.1%) |
| Surgery plus radiotherapy | 16 (42.1%) |
| Surgery plus concomitant chemoradiotherapy | 1 (2.6%) |
| Concomitant chemoradiotherapy | 5 (13.2%) |
| Radioimmunotherapy | 1 (2.6%) |
| Neoadjuvant chemotherapy plus surgery | 1 (2.6%) |
| Ind. chemotherapy plus radioimmunotherapy | 1 (2.6%) |
| Ind. radioimmunotherapy plus surgery (Study) | 1 (2.6%) |
| Salvage treatment of recurrence | |
| All | 13 |
| Surgery | 6 (46.2%) |
| Surgery plus radiotherapy | 6 (46.2%) |
| Radioimmunotherapy | 1 (7.7%) |
| Extent of disease | |
| Locoregional recurrence alone | 14 (36.8%) |
| Metastatic disease alone | 6 (15.8%) |
| Locoregional recurrence + metastatic disease | 18 (47.4%) |